MedTrace Logo

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers

NCT05900531 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-11-22

No results posted yet for this study

Summary

This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 alone, in combination with sitagliptin, or in combination with K-833.

Conditions

Interventions

DRUG

K-757

administered orally

DRUG

K-757 and open-label sitagliptin

both administered orally

DRUG

Matching placebo to K-757

administered orally

DRUG

Matching placebo to K-757 and matching placebo to K-833

both administered orally

DRUG

K-757 and K-833

both administered orally

DRUG

Matching placebo to K-757, open-label sitagliptin

both administered orally

Sponsors & Collaborators

  • Kallyope Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-21
Primary Completion
2023-05-03
Completion
2023-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05900531 on ClinicalTrials.gov